174 related articles for article (PubMed ID: 7749848)
21. Malondialdehyde affects the physico-chemical and biological characteristics of oxidized low density lipoprotein.
Aviram M
Atherosclerosis; 1990 Oct; 84(2-3):141-3. PubMed ID: 2282095
[TBL] [Abstract][Full Text] [Related]
22. Effects of methylmercury and trimethyltin on cardiac, platelet, and aorta eicosanoid biosynthesis and platelet serotonin release.
Ally A; Buist R; Mills P; Reuhl K
Pharmacol Biochem Behav; 1993 Mar; 44(3):555-63. PubMed ID: 8451259
[TBL] [Abstract][Full Text] [Related]
23. Platelet-modified low density lipoprotein induces macrophage cholesterol accumulation and platelet activation.
Aviram M; Fuhrman B; Keidar S; Maor I; Rosenblat M; Dankner G; Brook G
J Clin Chem Clin Biochem; 1989 Jan; 27(1):3-12. PubMed ID: 2498457
[TBL] [Abstract][Full Text] [Related]
24. Reversal by high-density lipoprotein of the effect of oxidized low-density lipoprotein on nitric oxide synthase protein expression in human platelets.
Mehta JL; Chen LY
J Lab Clin Med; 1996 Mar; 127(3):287-95. PubMed ID: 9273362
[TBL] [Abstract][Full Text] [Related]
25. Interaction of native and oxidized lipoprotein(a) with human mesangial cells and matrix.
Krämer-Guth A; Greiber S; Pavenstädt H; Quaschning T; Winkler K; Schollmeyer P; Wanner C
Kidney Int; 1996 May; 49(5):1250-61. PubMed ID: 8731088
[TBL] [Abstract][Full Text] [Related]
26. Lipoxidation products as biomarkers of oxidative damage to proteins during lipid peroxidation reactions.
Requena JR; Fu MX; Ahmed MU; Jenkins AJ; Lyons TJ; Thorpe SR
Nephrol Dial Transplant; 1996; 11 Suppl 5():48-53. PubMed ID: 9044307
[TBL] [Abstract][Full Text] [Related]
27. Benzodiazepines inhibit human platelet activation: comparison of the mechanism of antiplatelet actions of flurazepam and diazepam.
Romstedt K; Huzoor-Akbar
Thromb Res; 1985 May; 38(4):361-74. PubMed ID: 2990062
[TBL] [Abstract][Full Text] [Related]
28. Modified forms of low density lipoprotein affect platelet aggregation in vitro.
Aviram M
Thromb Res; 1989 Mar; 53(6):561-7. PubMed ID: 2734732
[TBL] [Abstract][Full Text] [Related]
29. Lipids and progression of renal disease: role of modified low density lipoprotein and lipoprotein(a).
Wanner C; Greiber S; Krämer-Guth A; Heinloth A; Galle J
Kidney Int Suppl; 1997 Dec; 63():S102-6. PubMed ID: 9407434
[TBL] [Abstract][Full Text] [Related]
30. Entire Peroxidation Reaction System of Myeloperoxidase Correlates with Progressive Low-Density Lipoprotein Modifications via Reactive Aldehydes in Atherosclerotic Patients with Hypertension.
Liu Q; Liu Y; Shi J; Gao M; Liu Y; Cong Y; Li Y; Wang Y; Yu M; Lu Y; Wang D; Chen S; Zheng Y; Cheng Y
Cell Physiol Biochem; 2018; 50(4):1245-1254. PubMed ID: 30355911
[TBL] [Abstract][Full Text] [Related]
31. Etofibrate increases binding of low and high density lipoprotein to human platelets of patients with type II hyperlipoproteinemia.
Virgolini I; Koller E; Li S; Yang Q; Banyai M; Rauscha F; Pidlich J; Pirker W; Sinzinger H
Atherosclerosis; 1993 Sep; 102(2):217-26. PubMed ID: 8251008
[TBL] [Abstract][Full Text] [Related]
32. Autoantibodies against malondialdehyde-modified lipoprotein(a) in antiphospholipid syndrome.
Romero FI; Atsumi T; Tinahones FJ; Gómez-Zumaquero JM; Amengual O; Khamashta MA; Hughes GR
Arthritis Rheum; 1999 Dec; 42(12):2606-11. PubMed ID: 10616007
[TBL] [Abstract][Full Text] [Related]
33. LDL-platelet interaction under oxidative stress induces macrophage foam cell formation.
Aviram M
Thromb Haemost; 1995 Jul; 74(1):560-4. PubMed ID: 8578524
[TBL] [Abstract][Full Text] [Related]
34. Prooxidant-initiated lipid peroxidation in isolated rat hepatocytes: detection of 4-hydroxynonenal- and malondialdehyde-protein adducts.
Hartley DP; Kroll DJ; Petersen DR
Chem Res Toxicol; 1997 Aug; 10(8):895-905. PubMed ID: 9282839
[TBL] [Abstract][Full Text] [Related]
35. Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein.
Palinski W; Ylä-Herttuala S; Rosenfeld ME; Butler SW; Socher SA; Parthasarathy S; Curtiss LK; Witztum JL
Arteriosclerosis; 1990; 10(3):325-35. PubMed ID: 1693068
[TBL] [Abstract][Full Text] [Related]
36. Native and oxidized low density lipoproteins enhance platelet aggregation in whole blood.
Tornvall P; Chirkova L; Toverud KD; Horowitz JD; Chirkov Y
Thromb Res; 1999 Aug; 95(4):177-83. PubMed ID: 10498387
[TBL] [Abstract][Full Text] [Related]
37. The influence of platelet-smooth muscle cell interaction on the oxidative modification of low-density lipoprotein.
Alexander JJ; Lewis I
J Surg Res; 2002 Mar; 103(1):41-6. PubMed ID: 11855916
[TBL] [Abstract][Full Text] [Related]
38. Oxidized LDL and reduction of the antiaggregating activity of nitric oxide derived from endothelial cells.
Minuz P; Lechi C; Gaino S; Bonapace S; Fontana L; Garbin U; Paluani F; Cominacini L; Zatti M; Lechi A
Thromb Haemost; 1995 Oct; 74(4):1175-9. PubMed ID: 8560431
[TBL] [Abstract][Full Text] [Related]
39. The molecular nature and consequences of lipoprotein (a)'s association with platelets.
Barre DE
Protein Pept Lett; 2007; 14(9):839-42. PubMed ID: 18045222
[TBL] [Abstract][Full Text] [Related]
40. Enhancement of platelet functions by low density lipoproteins.
Surya II; Gorter G; Mommersteeg M; Akkerman JW
Biochim Biophys Acta; 1992 Nov; 1165(1):19-26. PubMed ID: 1420343
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
